A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration
Clinical trial NCT00782093 · COMPLETED
Trial details
- NCT number
- NCT00782093
- Sponsor
- Ophthotech Corporation
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2008-10-01
- Primary completion
- 2012-06-01
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.